20多年前,早期乳腺癌随机对照试验的项目负责人同意将来自单个病人的数据每5年进行汇总并进行一系列总体再分析。这份协议,以“早期乳腺癌试验协作组”(EBCTCG)而闻名,对临床实践和病人带来了深远的影响,表现在主要依据 EBCTCG 研究结果的多种权威指南的发布,以及研究结果被各种报告引用10000多次。第四份总体报告达到了被引用的高峰(热点论文第1篇)。这 More than 20 years ago, project leaders in the randomized controlled trials of early breast cancers agreed to compile data from a single patient every 5 years and conduct a series of general reanalysis. Known for its association with the Early Breast Cancer Trial Group (EBCTCG), this agreement has had a profound impact on clinical practice and patient performance, as demonstrated by the publication of a number of authoritative guidelines based primarily on the results of the EBCTCG study, as well as research The results were quoted over 10,000 times in various reports. The fourth overall report reached the peak cited (Hot Paper # 1). This